ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för trofinetide. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

29 träffar

Bibliografisk träff 2024-03-23

Safety and efficacy of trofinetide in Rett syndrome: a systematic review and meta-analysis of randomized controlled trials.

Abbas A, Fayoud AM, El Din Moawad MH, Hamad AA, Hamouda H, Fouad EA.

BMC Pediatr · meta-analysis; research-article; systematic review; journal article · DOI 10.1186/s12887-024-04526-3

Bibliografisk träff 2024-03-19

Look at DAYBUE™ (Trofinetide) as first ever drug for treatment of Rett Syndrome.

Tareen MK, Mohiyuddin Z.

Asian J Psychiatr · letter · DOI 10.1016/j.ajp.2024.104011

Bibliografisk träff 2024-02-20

Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives.

Moore R, Poulsen J, Reardon L, Samples-Morris C, Simmons H, Ramsey KM, Whatley ML, Lane JB.

Adv Ther · clinical trial, phase iii; brief-report; journal article · DOI 10.1007/s12325-024-02782-4

Bibliografisk träff 2024-02-16

Exposure-Response Efficacy Modeling to Support Trofinetide Dosing in Individuals with Rett Syndrome.

Darwish M, Passarell J, Youakim JM, Bradley H, Bishop KM.

Adv Ther · clinical trial, phase iii; research support, non-u.s. gov't; research-article; journal article · DOI 10.1007/s12325-024-02796-y

Bibliografisk träff 2024-02-01

A Physiologically Based Pharmacokinetic Modeling Approach to Assess the Potential for Drug Interactions Between Trofinetide and CYP3A4-Metabolized Drugs.

Darwish M, Youakim JM, Darling I, Lukacova V, Owen JS, Bradley H.

Clin Ther · research support, non-u.s. gov't; journal article · DOI 10.1016/j.clinthera.2023.12.007

Bibliografisk träff 2024-01-22

Development of trofinetide for the treatment of Rett syndrome: from bench to bedside.

Kennedy M, Glass L, Glaze DG, Kaminsky S, Percy AK, Neul JL, Jones NE, Tropea D, Horrigan JP, Nues P, Bishop KM, Youakim JM.

Front Pharmacol · brief-report; journal article · DOI 10.3389/fphar.2023.1341746

Bibliografisk träff 2023-11-28

Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.

Darwish M, Nunez R, Youakim JM, Robertson P.

Clin Drug Investig · research-article; clinical trial, phase i; journal article · DOI 10.1007/s40261-023-01322-2

Bibliografisk träff 2023-11-23

Trofinetide Treatment Demonstrates a Benefit Over Placebo for the Ability to Communicate in Rett Syndrome.

Neul JL, Percy AK, Benke TA, Berry-Kravis EM, Glaze DG, Peters SU, Marsh ED, An D, Bishop KM, Youakim JM.

Pediatr Neurol · randomized controlled trial; journal article · DOI 10.1016/j.pediatrneurol.2023.11.005

Bibliografisk träff 2023-11-16

Trofinetide-a new chapter in rett syndrome's treatment.

Furqan M.

Front Pharmacol · brief-report; journal article · DOI 10.3389/fphar.2023.1284035

Bibliografisk träff 2023-11-01

Trofinetide in Rett syndrome: A brief review of safety and efficacy.

Singh A, Balasundaram MK, Gupta D.

Intractable Rare Dis Res · letter; journal article · DOI 10.5582/irdr.2023.01060

Bibliografisk träff 2023-08-04

Trofinetide for Rett Syndrome: Highlights on the Development and Related Inventions of the First USFDA-Approved Treatment for Rare Pediatric Unmet Medical Need.

Hudu SA, Elmigdadi F, Qtaitat AA, Almehmadi M, Alsaiari AA, Allahyani M, Aljuaid A, Salih M, Alghamdi A, Alrofaidi MA, Abida, Imran M.

J Clin Med · review-article; review; journal article · DOI 10.3390/jcm12155114

Bibliografisk träff 2023-07-28

A review of the Rett Syndrome Behaviour Questionnaire and its utilization in the assessment of symptoms associated with Rett syndrome.

Percy AK, Neul JL, Benke TA, Marsh ED, Glaze DG.

Front Pediatr · review-article; review; journal article · DOI 10.3389/fped.2023.1229553

Bibliografisk träff 2023-07-16

Trofinetide: a pioneering treatment for Rett syndrome.

Parent H, Ferranti A, Niswender C.

Trends Pharmacol Sci · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.tips.2023.06.008

Bibliografisk träff 2023-07-01

Trofinetide.

Författaruppgift saknas

Am J Health Syst Pharm · journal article · DOI 10.1093/ajhp/zxad097

Bibliografisk träff 2023-06-08

Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study.

Neul JL, Percy AK, Benke TA, Berry-Kravis EM, Glaze DG, Marsh ED, Lin T, Stankovic S, Bishop KM, Youakim JM.

Nat Med · clinical trial, phase iii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1038/s41591-023-02398-1

Bibliografisk träff 2023-06-01

Trofinetide: First Approval.

Keam SJ.

Drugs · review; journal article · DOI 10.1007/s40265-023-01883-8

Bibliografisk träff 2023-04-15

Trofinetide

Författaruppgift saknas

Tidskrift saknas · review

Bibliografisk träff 2023-04-01

Trofinetide Receives FDA Approval as First Drug for Rett Syndrome.

Harris E.

JAMA · journal article · DOI 10.1001/jama.2023.4003

Bibliografisk träff 2022-05-27

A Phase 1, Open-Label Study to Evaluate the Effects of Food and Evening Dosing on the Pharmacokinetics of Oral Trofinetide in Healthy Adult Subjects.

Darwish M, Youakim JM, Harlick J, DeKarske D, Stankovic S.

Clin Drug Investig · research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s40261-022-01156-4

Bibliografisk träff 2022-02-08

Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome.

Neul JL, Percy AK, Benke TA, Berry-Kravis EM, Glaze DG, Peters SU, Jones NE, Youakim JM.

Contemp Clin Trials · clinical trial protocol; research support, non-u.s. gov't; journal article · DOI 10.1016/j.cct.2022.106704

Bibliografisk träff 2020-05-23

A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome.

Berry-Kravis E, Horrigan JP, Tartaglia N, Hagerman R, Kolevzon A, Erickson CA, Hatti S, Snape M, Yaroshinsky A, Stoms G, FXS-001 Investigators, Glass L, Jones NE.

Pediatr Neurol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.pediatrneurol.2020.04.019

Bibliografisk träff 2019-03-27

Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome.

Glaze DG, Neul JL, Kaufmann WE, Berry-Kravis E, Condon S, Stoms G, Oosterholt S, Della Pasqua O, Glass L, Jones NE, Percy AK, Rett 002 Study Group.

Neurology · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1212/wnl.0000000000007316

Bibliografisk träff 2017-05-15

Population pharmacokinetics of NNZ-2566 in healthy subjects.

Oosterholt SP, Horrigan J, Jones N, Glass L, Della Pasqua O.

Eur J Pharm Sci · clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1016/j.ejps.2017.05.032

Bibliografisk träff 2015-01-23

NNZ-2566, a novel analog of (1-3) IGF-1, as a potential therapeutic agent for fragile X syndrome.

Deacon RM, Glass L, Snape M, Hurley MJ, Altimiras FJ, Biekofsky RR, Cogram P.

Neuromolecular Med · research support, non-u.s. gov't; journal article · DOI 10.1007/s12017-015-8341-2

Bibliografisk träff 2013-06-14

Mechanism of action for NNZ-2566 anti-inflammatory effects following PBBI involves upregulation of immunomodulator ATF3.

Cartagena CM, Phillips KL, Williams GL, Konopko M, Tortella FC, Dave JR, Schmid KE.

Neuromolecular Med · research support, non-u.s. gov't; journal article · DOI 10.1007/s12017-013-8236-z

Bibliografisk träff 2009-08-05

NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats.

Wei HH, Lu XC, Shear DA, Waghray A, Yao C, Tortella FC, Dave JR.

J Neuroinflammation · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1742-2094-6-19

Bibliografisk träff 2009-07-29

NNZ-2566, a glypromate analog, attenuates brain ischemia-induced non-convulsive seizures in rats.

Lu XC, Si Y, Williams AJ, Hartings JA, Gryder D, Tortella FC.

J Cereb Blood Flow Metab · research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1038/jcbfm.2009.109

Bibliografisk träff 2009-01-20

NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke.

Bickerdike MJ, Thomas GB, Batchelor DC, Sirimanne ES, Leong W, Lin H, Sieg F, Wen J, Brimble MA, Harris PW, Gluckman PD.

J Neurol Sci · journal article · DOI 10.1016/j.jns.2008.12.003

Bibliografisk träff 2009-01-01

NNZ-2566, a glypromate analog, improves functional recovery and attenuates apoptosis and inflammation in a rat model of penetrating ballistic-type brain injury.

Lu XC, Chen RW, Yao C, Wei H, Yang X, Liao Z, Dave JR, Tortella FC.

J Neurotrauma · research support, non-u.s. gov't; journal article · DOI 10.1089/neu.2008.0629